newsfilter
← Latest News
Business Wire·

CytRx Comments on Quarterly Results and Year-to-Date Progress

Continues Focusing on Near-Term Revenue Opportunities Linked to Orphazyme's Potential Regulatory Approvals for Arimoclomol in the Treatment of Niemann-Pick Disease Type C CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopha